---
document_datetime: 2024-12-11 11:49:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/ilaris-epar-all-authorised-presentations_en.pdf
document_name: ilaris-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9094769
conversion_datetime: 2025-12-25 03:35:15.886452
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form               | Route of administration   | Immediate Packaging                                        | Content (concentration)   | Pack size        |
|------------------|-------------------|------------|-----------------------------------|---------------------------|------------------------------------------------------------|---------------------------|------------------|
| EU/1/09/564/001  | ILARIS            | 150 mg     | Powder for solution for injection | Subcutaneous use          | vial (glass)                                               |                           | 1 vial           |
| EU/1/09/564/002  | ILARIS            | 150 mg     | Powder for solution for injection | Subcutaneous use          | vial (glass)                                               |                           | 4 (1 x 4) vials  |
| EU/1/09/564/004  | ILARIS            | 150 mg/ml  | Solution for injection            | Subcutaneous use          | vial (glass)                                               | 1 ml                      | 1 vial           |
| EU/1/09/564/005  | ILARIS            | 150 mg     | Solution for injection            | Subcutaneous use          | pre-filled syringe (glass) in pre- filled pen (SensoReady) | 1 ml (150 mg/ml)          | 1 pre-filled pen |